The hemostatic system in patients with type 2 diabetes with and without cardiovascular disease

Chantal J. N. Verkleij; Roderick E. de Bruijn; Eelco W. Meesters; Victor E. A. Gerdes; Joost C. M. Meijers; Pauline F. Marx

doi:10.1177/1076029610384112

The hemostatic system in patients with type 2 diabetes with and without cardiovascular disease

Chantal J. N. Verkleij
, Roderick E. de Bruijn
, Eelco W. Meesters
, Victor E. A. Gerdes
, Joost C. M. Meijers
, Pauline F. Marx

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

The contribution of the hemostatic system in the development of cardiovascular disease (CVD) in patients with type 2 diabetes is not completely defined. The aim of this study was to elucidate associations of hemostatic factors with the development of CVD in patients with type 2 diabetes. Patients with type 2 diabetes without CVD (n = 113), with CVD (n = 94), and controls without CVD (n = 100) were enrolled in this study. Several hemostatic markers were measured. A disturbed hemostatic balance in patients with type 2 diabetes was observed as illustrated by hypofibrinolysis and increased levels of von Willebrand factor (vWF) and plasminogen-activator inhibitor 1 (PAI-1). Patients with type 2 diabetes with CVD have more thrombin generation compared to patients without CVD. This hemostatic imbalance might contribute to the development of CVD in patients with type 2 diabetes

Original language	English
Pages (from-to)	E57-E63
Journal	Clinical and applied thrombosis/hemostasis
Volume	17
Issue number	6
DOIs	https://doi.org/10.1177/1076029610384112
Publication status	Published - 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1177/1076029610384112

Cite this

@article{abd09cd7262b4b3fa8c16260f362d5e5,

title = "The hemostatic system in patients with type 2 diabetes with and without cardiovascular disease",

abstract = "The contribution of the hemostatic system in the development of cardiovascular disease (CVD) in patients with type 2 diabetes is not completely defined. The aim of this study was to elucidate associations of hemostatic factors with the development of CVD in patients with type 2 diabetes. Patients with type 2 diabetes without CVD (n = 113), with CVD (n = 94), and controls without CVD (n = 100) were enrolled in this study. Several hemostatic markers were measured. A disturbed hemostatic balance in patients with type 2 diabetes was observed as illustrated by hypofibrinolysis and increased levels of von Willebrand factor (vWF) and plasminogen-activator inhibitor 1 (PAI-1). Patients with type 2 diabetes with CVD have more thrombin generation compared to patients without CVD. This hemostatic imbalance might contribute to the development of CVD in patients with type 2 diabetes",

author = "Verkleij, \{Chantal J. N.\} and Bruijn, \{Roderick E. de\} and Meesters, \{Eelco W.\} and Gerdes, \{Victor E. A.\} and Meijers, \{Joost C. M.\} and Marx, \{Pauline F.\}",

year = "2011",

doi = "10.1177/1076029610384112",

language = "English",

volume = "17",

pages = "E57--E63",

journal = "Clinical and applied thrombosis/hemostasis",

issn = "1076-0296",

publisher = "SAGE Publications Inc.",

number = "6",

}

TY - JOUR

T1 - The hemostatic system in patients with type 2 diabetes with and without cardiovascular disease

AU - Verkleij, Chantal J. N.

AU - Bruijn, Roderick E. de

AU - Meesters, Eelco W.

AU - Gerdes, Victor E. A.

AU - Meijers, Joost C. M.

AU - Marx, Pauline F.

PY - 2011

Y1 - 2011

N2 - The contribution of the hemostatic system in the development of cardiovascular disease (CVD) in patients with type 2 diabetes is not completely defined. The aim of this study was to elucidate associations of hemostatic factors with the development of CVD in patients with type 2 diabetes. Patients with type 2 diabetes without CVD (n = 113), with CVD (n = 94), and controls without CVD (n = 100) were enrolled in this study. Several hemostatic markers were measured. A disturbed hemostatic balance in patients with type 2 diabetes was observed as illustrated by hypofibrinolysis and increased levels of von Willebrand factor (vWF) and plasminogen-activator inhibitor 1 (PAI-1). Patients with type 2 diabetes with CVD have more thrombin generation compared to patients without CVD. This hemostatic imbalance might contribute to the development of CVD in patients with type 2 diabetes

AB - The contribution of the hemostatic system in the development of cardiovascular disease (CVD) in patients with type 2 diabetes is not completely defined. The aim of this study was to elucidate associations of hemostatic factors with the development of CVD in patients with type 2 diabetes. Patients with type 2 diabetes without CVD (n = 113), with CVD (n = 94), and controls without CVD (n = 100) were enrolled in this study. Several hemostatic markers were measured. A disturbed hemostatic balance in patients with type 2 diabetes was observed as illustrated by hypofibrinolysis and increased levels of von Willebrand factor (vWF) and plasminogen-activator inhibitor 1 (PAI-1). Patients with type 2 diabetes with CVD have more thrombin generation compared to patients without CVD. This hemostatic imbalance might contribute to the development of CVD in patients with type 2 diabetes

U2 - 10.1177/1076029610384112

DO - 10.1177/1076029610384112

M3 - Article

C2 - 21078616

SN - 1076-0296

VL - 17

SP - E57-E63

JO - Clinical and applied thrombosis/hemostasis

JF - Clinical and applied thrombosis/hemostasis

IS - 6

ER -

The hemostatic system in patients with type 2 diabetes with and without cardiovascular disease

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this